Market News How it works Learn FAQ
| RCT 0.084 10.38% | NU 12.59 -16.95% | EWZ 34.15 -19.82% | BBD 2.93 -28.01% | TGL 0.2377 7.31% | AZTR 1.51 111.19% | ITUB 7.7 -20.37% | XP 15.705 -48.36% | NVD 3.99 -4.77% | SRTM 0.3 -30.28% | WFF 0.0898 12.25% | SPCX 146.9 -0.40% | PBR 22.5 -13.99% | SOXL 90.5 8.31% | INTC 90.47 4.04% | SHFS 0.094 -29.00% | VALE 12 -3.23% | NVDA 216.019 2.40% | CLRO 4.97 52.92% | NOK 8.64 6.14% | TSLL 10.76 10.25% | JBLU 2.37 -9.71% | CRWV 55.19 1.76% | GCDT 0.1497 -14.99% | SOXS 47.98 -8.54% | ABEV 2.83 -14.24% | NWGL 0.0857 4.51% | RWM 14.5 -0.34% | BITO 10.65 -1.66% | AAL 12.2 0.74% | RIG 6.53 1.87% | GPUS 0.1785 5.68% | TSLG 5.38 10.47% | T 20.85 -0.38% | SGRY 23.25 47.62% | IREN 25.43 2.11% | INTR 4.68 -34.91% | SBS 4.73 -26.09% | NFLX 63.9 -2.96% | GRAB 2.71 -2.87% | TSLA 391.62 5.21% | QID 14.22 -2.27% | WULF 11.98 5.83% | TQQQ 68.43 3.23% | CIFR 7.71 -2.90% | SID 0.9118 -22.73% | RBNE 0.1671 -12.05% | SPDN 8.5 -0.47% | VZ 43.1 -3.49% | PLUG 1.37 -0.72%
CHChannel Therapeutics Corporation logo

Channel Therapeutics Corporation (CHRO)

New York Stock Exchange Arca · Currency in USD
$1.35 ▲ +0.09 (+7.14%)
At close: Jul 1, 4:00 PM ET. Market closed.
$1.37 ▲ +0.02 (+1.47%)
After hours: Jul 1, 7:50 PM ET

Summary

Previous Close
$1.26
Open
$1.25
Day's Range
$1.23 – $1.48
52 Week Range
$1.23 – $54.29
Volume
193,120
Avg. Volume
76,399
Market Cap
$8.90M
Beta (5Y Monthly)
3.29
PE Ratio (TTM)
--
EPS (TTM)
-$20.22
Earnings Date
--
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
--

Profile: Channel Therapeutics Corporation

Sector
Healthcare
Industry
Biotechnology
Full-time employees
4
CEO
Francis Knuettel II,

Channel Therapeutics Corporation operates as a clinical-stage biotechnology company, committed to the entire process of identifying, advancing, and bringing to market novel therapies aimed at reducing pain. Its research strategy centers on precisely inhibiting the NaV1.7 sodium ion-channel, in addition to other related receptors within the broader NaV family. The firm's flagship investigational drug, CC8464, is currently undergoing Phase 2a clinical evaluation.

Earnings

DateEst.Actual
Mar 19, 2026–-$1.15
Nov 13, 2025–-$5.30
Aug 12, 2025–-$0.31
May 13, 2025–-$0.32
Mar 27, 2025-$0.21-$0.32Miss
Nov 13, 2024-$0.23-$0.29Miss

Analyst view

Rating: Buy
Buy 100% · Hold 0% · Sell 0%

Get free alerts on CHRO and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.